{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T14:30:59Z","timestamp":1779114659354,"version":"3.51.4"},"posted":{"date-parts":[[2026,3,6]]},"group-title":"Epidemiology","reference-count":41,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,3,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Neurodegenerative diseases (NDDs) including Alzheimer\u2019s disease (AD), Parkinson\u2019s disease (PD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and non-AD dementias share chronic neuroinflammatory mechanisms that contribute to neuronal injury and disease progression. While anti-inflammatory therapies (AITs) are associated with reduced neurodegenerative disease risk, knowledge regarding the impact of biological sex and treatment duration across multiple NDDs remains limited.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a retrospective cohort analysis using a large propensity-score-matched population (n = 190,308; 95,154 treated vs 95,154 untreated) to evaluate associations between long-term AIT exposure and incidence of major NDDs. Disease-specific and combined outcomes were assessed across drug classes (NSAIDs, corticosteroids, immunomodulators), sex, age, and therapy duration.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>AIT exposure was associated with a significantly lower risk of developing any NDD (RR = 0.47, 95% CI 0.43\u20130.48, p &lt; .0001) and was equally effective in both sexes. Risk reduction was observed for each individual disease: AD (RR = 0.40), non-AD dementia (RR = 0.51), PD (RR = 0.43), MS (RR = 0.25), and ALS (RR = 0.48). Among drug classes, immunomodulators conferred the largest reduction (RR = 0.19), followed by corticosteroids (RR = 0.41) and NSAIDs (RR = 0.42). Duration analyses revealed a graded benefit, with RR declining from 0.94 (&lt;1 year) to 0.25 (&gt;6 years). Risk reduction was strongest in older participants (75\u201379 years).<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>Chronic use of anti-inflammatory or immunomodulatory therapies was associated with substantially reduced incidence of multiple neurodegenerative diseases in both sexes. The strongest effects were observed with immunomodulator use and prolonged therapy duration, suggesting that sustained modulation of systemic inflammation confers broad neuroprotective effects in both sexes. These findings highlight the potential of targeting immune-inflammatory pathways for neurodegenerative disease prevention and can inform prospective mechanistic and interventional studies.<\/jats:p>\n                <\/jats:sec>","DOI":"10.64898\/2026.03.06.26347446","type":"posted-content","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:20:17Z","timestamp":1772842817000},"source":"Crossref","is-referenced-by-count":1,"title":["Immunotherapies for risk reduction in age-associated neurodegenerative diseases: impact of sex and treatment duration"],"prefix":"10.64898","author":[{"given":"Helena","family":"Cortes-Flores","sequence":"first","affiliation":[{"name":"Center for Innovation in Brain Science, University of Arizona, Tucson, AZ, United States"},{"name":"Department of Pharmacology, University of Arizona College of Medicine, Tucson, AZ, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgina","family":"Torrandell-Haro","sequence":"additional","affiliation":[{"name":"Center for Innovation in Brain Science, University of Arizona, Tucson, AZ, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta Diaz","family":"Brinton","sequence":"additional","affiliation":[{"name":"Center for Innovation in Brain Science, University of Arizona, Tucson, AZ, United States"},{"name":"Department of Pharmacology, University of Arizona College of Medicine, Tucson, AZ, United States"},{"name":"Department of Neurology, University of Arizona College of Medicine, Tucson, AZ, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2026030911450979000_2026.03.06.26347446v1.1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13809"},{"key":"2026030911450979000_2026.03.06.26347446v1.2","first-page":"e4620","article-title":"Recommendations for Anti-inflammatory Treatments in Alzheimer\u2019s Disease: A Comprehensive Review of the Literature","volume":"11","year":"2019","journal-title":"Cureus"},{"key":"2026030911450979000_2026.03.06.26347446v1.3","doi-asserted-by":"crossref","first-page":"e70514","DOI":"10.1002\/alz.70514","article-title":"Cytokines and immune biomarkers in neurodegeneration and cognitive function: A systematic review among individuals of African ancestry","volume":"21","year":"2025","journal-title":"Alzheimers Dement"},{"key":"2026030911450979000_2026.03.06.26347446v1.4","doi-asserted-by":"crossref","unstructured":"Ashraf, H. , Solla, P. & Sechi, L. A . 2022. Current Advancement of Immunomodulatory Drugs as Potential Pharmacotherapies for Autoimmunity Based Neurological Diseases. Pharmaceuticals (Basel ), 15.","DOI":"10.3390\/ph15091077"},{"key":"2026030911450979000_2026.03.06.26347446v1.5","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.123"},{"key":"2026030911450979000_2026.03.06.26347446v1.6","doi-asserted-by":"crossref","first-page":"e201541","DOI":"10.1001\/jamanetworkopen.2020.1541","article-title":"Association Between Hormone-Modulating Breast Cancer Therapies and Incidence of Neurodegenerative Outcomes for Women With Breast Cancer","volume":"3","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2026030911450979000_2026.03.06.26347446v1.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2016.02.010"},{"key":"2026030911450979000_2026.03.06.26347446v1.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2024.03.010"},{"key":"2026030911450979000_2026.03.06.26347446v1.9","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.3892\/mmr.2016.4948","article-title":"Role of neuroinflammation in neurodegenerative diseases (Review)","volume":"13","year":"2016","journal-title":"Mol Med Rep"},{"key":"2026030911450979000_2026.03.06.26347446v1.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.02.043"},{"key":"2026030911450979000_2026.03.06.26347446v1.11","doi-asserted-by":"publisher","DOI":"10.1124\/pr.117.014647"},{"key":"2026030911450979000_2026.03.06.26347446v1.12","doi-asserted-by":"crossref","first-page":"e12445","DOI":"10.1002\/trc2.12445","article-title":"Baricitinib and tofacitinib off-target profile, with a focus on Alzheimer\u2019s disease","volume":"10","year":"2024","journal-title":"Alzheimers Dement (N Y"},{"key":"2026030911450979000_2026.03.06.26347446v1.13","unstructured":"Fine, M . 2013 Nov. Quantifying the impact of NSAID-associated adverse events. . Am J Manag Care, s267\u201372."},{"key":"2026030911450979000_2026.03.06.26347446v1.14","doi-asserted-by":"crossref","unstructured":"Giri, P. M. , Banerjee, A. , Ghosal, A. & Layek, B . 2024. Neuroinflammation in Neurodegenerative Disorders: Current Knowledge and Therapeutic Implications. Int J Mol Sci, 25.","DOI":"10.3390\/ijms25073995"},{"key":"2026030911450979000_2026.03.06.26347446v1.15","doi-asserted-by":"crossref","unstructured":"Gonzales, M. M. , Garbarino, V. R. , Pollet, E. , Palavicini, J. P. , Kellogg, D. L. , JR., Kraig, E. & Orr, M. E . 2022. Biological aging processes underlying cognitive decline and neurodegenerative disease. J Clin Invest, 132.","DOI":"10.1172\/JCI158453"},{"key":"2026030911450979000_2026.03.06.26347446v1.16","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24897"},{"key":"2026030911450979000_2026.03.06.26347446v1.17","doi-asserted-by":"publisher","DOI":"10.1177\/1533317514542644"},{"key":"2026030911450979000_2026.03.06.26347446v1.18","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)70016-5"},{"key":"2026030911450979000_2026.03.06.26347446v1.19","unstructured":"Hsiao CJ , C. D., Beatty PC , Rechtsteiner EA . 2010. National Ambulatory Medical Care Survey: 2007 summary. . Natl Health Stat Report., 1-32."},{"key":"2026030911450979000_2026.03.06.26347446v1.20","doi-asserted-by":"crossref","first-page":"e12174","DOI":"10.1002\/trc2.12174","article-title":"Association between menopausal hormone therapy and risk of neurodegenerative diseases: Implications for precision hormone therapy","volume":"7","year":"2021","journal-title":"Alzheimers Dement (N Y"},{"key":"2026030911450979000_2026.03.06.26347446v1.21","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.90"},{"key":"2026030911450979000_2026.03.06.26347446v1.22","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40035-020-00221-2","article-title":"Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes","volume":"9","year":"2020","journal-title":"Transl Neurodegener"},{"key":"2026030911450979000_2026.03.06.26347446v1.23","doi-asserted-by":"crossref","unstructured":"Lamptey, R. N. L. , Chaulagain, B. , Trivedi, R. , Gothwal, A. , Layek, B. & Singh, J . 2022. A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Nanotherapeutics. Int J Mol Sci, 23.","DOI":"10.3390\/ijms23031851"},{"key":"2026030911450979000_2026.03.06.26347446v1.24","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-020-00435-y"},{"key":"2026030911450979000_2026.03.06.26347446v1.25","doi-asserted-by":"publisher","DOI":"10.1186\/1710-1492-9-30"},{"key":"2026030911450979000_2026.03.06.26347446v1.26","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-015-0239-z"},{"key":"2026030911450979000_2026.03.06.26347446v1.27","unstructured":"Owais Qureshi, A. D. 2023. COX Inhibitors. StatPearls [Internet]: StatPearls Publishing."},{"key":"2026030911450979000_2026.03.06.26347446v1.28","doi-asserted-by":"crossref","first-page":"e00795","DOI":"10.1002\/prp2.795","article-title":"Immunomodulation induced by central nervous system-related peptides as a therapeutic strategy for neurodegenerative disorders","volume":"9","year":"2021","journal-title":"Pharmacol Res Perspect"},{"key":"2026030911450979000_2026.03.06.26347446v1.29","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.201"},{"key":"2026030911450979000_2026.03.06.26347446v1.30","unstructured":"Sharman, A. H. T . 2023. Corticosteroids. Treasure Island (FL): StatPearls."},{"key":"2026030911450979000_2026.03.06.26347446v1.31","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)30173-8. PubMed PMID: 27156434."},{"key":"2026030911450979000_2026.03.06.26347446v1.32","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12922"},{"key":"2026030911450979000_2026.03.06.26347446v1.33","doi-asserted-by":"crossref","first-page":"1127704","DOI":"10.3389\/fimmu.2023.1127704","article-title":"Immunomodulation-a general review of the current state-of-the-art and new therapeutic strategies for targeting the immune system","volume":"14","year":"2023","journal-title":"Front Immunol"},{"key":"2026030911450979000_2026.03.06.26347446v1.34","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12108"},{"key":"2026030911450979000_2026.03.06.26347446v1.35","unstructured":"U.S. Food and Drug Administration (FDA). 2020. What are \u201cbiologics\u201d questions and answers. [Online]. Available: https:\/\/www.fda.gov\/about-fda\/center-biologics-evaluation-and-research-cber\/what-are-biologics-questions-and-answers [Accessed]."},{"key":"2026030911450979000_2026.03.06.26347446v1.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2016.03.010"},{"key":"2026030911450979000_2026.03.06.26347446v1.37","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4305"},{"key":"2026030911450979000_2026.03.06.26347446v1.38","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3233\/JAD-141506","article-title":"Anti-inflammatory drugs and risk of Alzheimer\u2019s disease: an updated systematic review and meta-analysis","volume":"44","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"2026030911450979000_2026.03.06.26347446v1.39","doi-asserted-by":"crossref","first-page":"348","DOI":"10.5114\/fn.2024.145758","article-title":"S1P receptor modulators affect the toxicity of amyloid beta oligomers in microglial and neuronal cells","volume":"62","year":"2024","journal-title":"Folia Neuropathol"},{"key":"2026030911450979000_2026.03.06.26347446v1.40","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41392-023-01486-5","article-title":"Role of neuroinflammation in neurodegeneration development","volume":"8","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"2026030911450979000_2026.03.06.26347446v1.41","doi-asserted-by":"crossref","first-page":"128229","DOI":"10.1016\/j.bmcl.2021.128229","article-title":"Small molecule approaches to treat autoimmune and inflammatory diseases (Part III): Targeting cytokines and cytokine receptor complexes","volume":"48","year":"2021","journal-title":"Bioorg Med Chem Lett"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.03.06.26347446","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T18:45:19Z","timestamp":1773081919000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.64898\/2026.03.06.26347446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":41,"URL":"https:\/\/doi.org\/10.64898\/2026.03.06.26347446","relation":{},"subject":[],"published":{"date-parts":[[2026,3,6]]},"subtype":"preprint"}}